Array ( [0] => WP_Term Object ( [term_id] => 16 [name] => UpRi (XMT-1536) [slug] => xmt-1536 [term_group] => 0 [term_taxonomy_id] => 16 [taxonomy] => category [description] => [parent] => 9 [count] => 10 [filter] => raw [cat_ID] => 16 [category_count] => 10 [category_description] => [cat_name] => UpRi (XMT-1536) [category_nicename] => xmt-1536 [category_parent] => 9 ) [1] => WP_Term Object ( [term_id] => 15 [name] => XMT-1522 [slug] => xmt-1522 [term_group] => 0 [term_taxonomy_id] => 15 [taxonomy] => category [description] => [parent] => 9 [count] => 4 [filter] => raw [cat_ID] => 15 [category_count] => 4 [category_description] => [cat_name] => XMT-1522 [category_nicename] => xmt-1522 [category_parent] => 9 ) [2] => WP_Term Object ( [term_id] => 17 [name] => XMT-1592 [slug] => xmt-1592 [term_group] => 0 [term_taxonomy_id] => 17 [taxonomy] => category [description] => [parent] => 9 [count] => 1 [filter] => raw [cat_ID] => 17 [category_count] => 1 [category_description] => [cat_name] => XMT-1592 [category_nicename] => xmt-1592 [category_parent] => 9 ) [3] => WP_Term Object ( [term_id] => 18 [name] => XMT-1660 [slug] => xmt-1660 [term_group] => 0 [term_taxonomy_id] => 18 [taxonomy] => category [description] => [parent] => 9 [count] => 1 [filter] => raw [cat_ID] => 18 [category_count] => 1 [category_description] => [cat_name] => XMT-1660 [category_nicename] => xmt-1660 [category_parent] => 9 ) [4] => WP_Term Object ( [term_id] => 19 [name] => XMT-2056 [slug] => xmt-2056 [term_group] => 0 [term_taxonomy_id] => 19 [taxonomy] => category [description] => [parent] => 9 [count] => 3 [filter] => raw [cat_ID] => 19 [category_count] => 3 [category_description] => [cat_name] => XMT-2056 [category_nicename] => xmt-2056 [category_parent] => 9 ) )

Array ( [99] => WP_Term Object ( [term_id] => 19 [name] => XMT-2056 [slug] => xmt-2056 [term_group] => 0 [term_taxonomy_id] => 19 [taxonomy] => category [description] => [parent] => 9 [count] => 3 [filter] => raw [cat_ID] => 19 [category_count] => 3 [category_description] => [cat_name] => XMT-2056 [category_nicename] => xmt-2056 [category_parent] => 9 ) [28] => WP_Term Object ( [term_id] => 18 [name] => XMT-1660 [slug] => xmt-1660 [term_group] => 0 [term_taxonomy_id] => 18 [taxonomy] => category [description] => [parent] => 9 [count] => 1 [filter] => raw [cat_ID] => 18 [category_count] => 1 [category_description] => [cat_name] => XMT-1660 [category_nicename] => xmt-1660 [category_parent] => 9 ) [25] => WP_Term Object ( [term_id] => 17 [name] => XMT-1592 [slug] => xmt-1592 [term_group] => 0 [term_taxonomy_id] => 17 [taxonomy] => category [description] => [parent] => 9 [count] => 1 [filter] => raw [cat_ID] => 17 [category_count] => 1 [category_description] => [cat_name] => XMT-1592 [category_nicename] => xmt-1592 [category_parent] => 9 ) [20] => WP_Term Object ( [term_id] => 16 [name] => UpRi (XMT-1536) [slug] => xmt-1536 [term_group] => 0 [term_taxonomy_id] => 16 [taxonomy] => category [description] => [parent] => 9 [count] => 10 [filter] => raw [cat_ID] => 16 [category_count] => 10 [category_description] => [cat_name] => UpRi (XMT-1536) [category_nicename] => xmt-1536 [category_parent] => 9 ) [10] => WP_Term Object ( [term_id] => 15 [name] => XMT-1522 [slug] => xmt-1522 [term_group] => 0 [term_taxonomy_id] => 15 [taxonomy] => category [description] => [parent] => 9 [count] => 4 [filter] => raw [cat_ID] => 15 [category_count] => 4 [category_description] => [cat_name] => XMT-1522 [category_nicename] => xmt-1522 [category_parent] => 9 ) )

Publications
Search by:
Platform
DolaLock (16)
Dolaflexin (14)
Dolasynthen (6)
Immunosynthen (8)
Other (3)
Program
XMT-2056 (3)
XMT-1660 (1)
XMT-1592 (1)
UpRi (XMT-1536) (10)
XMT-1522 (4)
Year
2021
2020
2019
2018
2017
2016
2015
2014
2013

XMT-2056, a well-tolerated, Immunosynthen-based STING-agonist antibody-drug conjugate which induces anti-tumor immune activity

American Association for Cancer Research (AACR)

April, 2021

Tumor cell-intrinsic STING pathway activation leads to robust induction of Type III Interferons and contributes to the anti-tumor activity elicited by STING agonism

Tumor cell-intrinsic STING pathway is activated in the presence of cues from immune cells and contributes to the anti-tumor activity of tumor cell-targeted STING agonist antibody-drug conjugates

Society for Immunotherapy of Cancer (SITC)

November, 2020

Safety and Efficacy of XMT-1536 in Ovarian Cancer: A Subgroup Analysis from the Phase 1 Expansion Study of XMT-1536, a NaPi2b Antibody-Drug Conjugate

Systemic Administration of STING Agonist Antibody-Drug Conjugates Elicit Potent Anti-Tumor Immune Responses with Minimal Induction of Circulating Cytokines

American Association for Cancer Research (AACR)

June, 2020

XMT-1592, a Site-Specific Dolasynthen-Based NaPi2b-Targeted Antibody-Drug Conjugate for the Treatment of Ovarian Cancer and Lung Adenocarcinoma

American Association for Cancer Research (AACR)

June, 2020

Phase 1 expansion study of XMT-1536, a novel NaPi2b-targeting antibody-drug conjugate (ADC): Preliminary efficacy, safety, and biomarker results in patients with previously treated metastatic ovarian cancer (OC) or non-small cell lung cancer (NSCLC)

Simultaneous quantification of total antibody and antibody-conjugated drug for XMT-1522 in human plasma using immunocapture-liquid chromatography/mass spectrometry.

Journal of Pharmaceutical and Biomedical Analysis, Volume 174, 10 September 2019, Pages 441-449

September, 2019

Phase 1 dose escalation study of XMT-1536, a novel NaPi2b-targeting antibody-drug conjugate (ADC), in patients (pts) with solid tumors likely to express NaPi2b

An Antibody-Drug Conjugate Carrying a Microtubule Inhibitor and a DNA Alkylator Exerts Both Mechanisms of Action on Tumor Cells

American Association for Cancer Research (AACR)

March, 2019

Target Expression/Efficacy Relationship of XMT-1522, a HER2-targeting Antibody Drug Conjugate (ADC), in an Unselected Series of Non-small Cell Lung Cancer (NSCLC) Primary Human Carcinoma Xenografts.

Indole-Biaryl Pyrrolobenzodiazepines (I-BiPs): A Potent and Well-tolerated Class of DNA Mono-alkylating Payload for Antibody-Drug Conjugates (ADCs)

AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

November, 2018

MERS67 is a Novel anti-NaPi2b Antibody and Demonstrates Differential Expression Patterns in Lung Cancer Histologic Subtypes

International Association for the Study of Lung Cancer (IASLC)

September, 2018

Phase 1 dose escalation of XMT-1522, a novel HER2-targeting antibody-drug conjugate (ADC), in patients with HER2-expressing breast, lung and gastric cancer

Synergy of an anti-HER2 ADC TAK-522 (XMT-1522) in combination with anti-PD1 mAb in a syngeneic breast cancer model expressing human HER2

American Association for Cancer Research (AACR)

April, 2018

Relationship of NaPi2b expression and efficacy of XMT-1536, a NaPi2b targeting antibody drug conjugate (ADC), in an unselected panel of human primary ovarian mouse xenograft models

AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

October, 2017

A phase Ib, first-in-human, dose escalation and expansion study of XMT-1522, a novel antibody-drug conjugate (ADC) directed against HER2, in patients with advanced breast cancer and other advanced tumors expressing HER2

June, 2017

Non-clinical pharmacokinetics of XMT-1522, a HER2 targeting auristatin-based antibody drug conjugate

April, 2017

Combination of anti-HER2 ADC XMT-1522 and checkpoint inhibitor pembrolizumab for treatment of NSCLC in preclinical models

April, 2017

A NaPi2b Antibody-Drug Conjugate Induces Durable Complete Tumor Regressions in Patient-Derived Xenograft Models of NSCLC

December, 2016

Discovery and preclinical development of a highly potent NaPi2b-targeted antibody-drug conjugate (ADC) with significant activity in patient-derived non-small cell lung cancer (NSCLC) xenograft models

April, 2016

Optimization of lead antibody selection for XMT-1522, a novel, highly potent HER2-targeted antibody-drug conjugate (ADC)

April, 2016

XMT-1522 induces tumor regressions in pre-clinical models representing HER2-positive and HER2 low-expressing breast cancer.

December, 2015

A Polymer-Based Antibody–Vinca Drug Conjugate Platform: Characterization and Preclinical Efficacy

June, 2015

A novel, highly potent HER2-targeted antibody-drug conjugate (ADC) for the treatment of low HER2-expressing tumors and combination with trastuzumab-based regimens in HER2-driven tumors

April, 2015

Trastuzumab-Dolaflexin, a Highly Potent Fleximer-Based Antibody-Drug Conjugate, Demonstrates a Favorable Therapeutic Index in Exploratory Toxicology Studies in Multiple Species

April, 2015

XMT-2056: Tumor-targeted Innate Immune Activation via a STING-agonist Antibody Drug Conjugate

AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Site Specific Dolasynthen ADCs demonstrate consistent exposure across a wide range of drug-to-antibody ratios

AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

XMT-1660, a B7-H4-Targeted Dolasynthen Antibody-Drug Conjugate for the Treatment of Breast Cancer

American Association for Cancer Research (AACR)

XMT-2056, a well-tolerated, Immunosynthen-based STING-agonist antibody-drug conjugate which induces anti-tumor immune activity

American Association for Cancer Research (AACR)

Tumor cell-intrinsic STING pathway activation leads to robust induction of Type III Interferons and contributes to the anti-tumor activity elicited by STING agonism

American Association for Cancer Research (AACR)

Dolaflexin: A Novel Antibody-Drug Conjugate Platform Featuring High Drug Loading and a Controlled Bystander Effect

Molecular Cancer Therapeutics, a journal of the American Association for Cancer Research (AACR)

The Dolaflexin-based antibody-drug conjugate XMT-1536 targets the solid tumor lineage antigen SLC34A2/NaPi2b

Molecular Cancer Therapeutics, a journal of the American Association for Cancer Research (AACR)

Tumor cell-intrinsic STING pathway is activated in the presence of cues from immune cells and contributes to the anti-tumor activity of tumor cell-targeted STING agonist antibody-drug conjugates

Society for Immunotherapy of Cancer (SITC)

Safety and Efficacy of XMT-1536 in Ovarian Cancer: A Subgroup Analysis from the Phase 1 Expansion Study of XMT-1536, a NaPi2b Antibody-Drug Conjugate

European Society of Medical Oncology (ESMO)

Tumor Targeting of a STING Agonist by Means of an Antibody-Drug Conjugate Induces Potent Anti-Tumor Immune Responses

Innate Immunity Stimulating Therapies Summit

Systemic Administration of STING Agonist Antibody-Drug Conjugates Elicit Potent Anti-Tumor Immune Responses with Minimal Induction of Circulating Cytokines

American Association for Cancer Research (AACR)

XMT-1592, a Site-Specific Dolasynthen-Based NaPi2b-Targeted Antibody-Drug Conjugate for the Treatment of Ovarian Cancer and Lung Adenocarcinoma

American Association for Cancer Research (AACR)

Phase 1 expansion study of XMT-1536, a novel NaPi2b-targeting antibody-drug conjugate (ADC): Preliminary efficacy, safety, and biomarker results in patients with previously treated metastatic ovarian cancer (OC) or non-small cell lung cancer (NSCLC)

American Society of Clinical Oncology (ASCO)

A Phase 1 study of XMT-1536 in patients with solid tumors likely to express NaPi2b: A summary of dose escalation

SGO 2020 Annual Meeting on Women’s Cancer

Tumor targeting of a STING agonist with an antibody drug conjugate elicits potent anti-tumor immune responses

Society for Immunotherapy of Cancer (SITC)

NaPi2b Expression in a Large Surgical Non-Small Cell Lung Cancer (NSCLC) Cohort

AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Mersana’s Innovative ADC Platforms – World ADC Summit 2019

World ADC Summit

Simultaneous quantification of total antibody and antibody-conjugated drug for XMT-1522 in human plasma using immunocapture-liquid chromatography/mass spectrometry.

Journal of Pharmaceutical and Biomedical Analysis, Volume 174, 10 September 2019, Pages 441-449

Phase 1 dose escalation study of XMT-1536, a novel NaPi2b-targeting antibody-drug conjugate (ADC), in patients (pts) with solid tumors likely to express NaPi2b

American Society of Clinical Oncology (ASCO)

Dolasynthen: A Novel, Homogeneous Auristatin F Hydroxypropyl Amide Antibody-Drug Conjugate Platform

American Association for Cancer Research (AACR)

An Antibody-Drug Conjugate Carrying a Microtubule Inhibitor and a DNA Alkylator Exerts Both Mechanisms of Action on Tumor Cells

American Association for Cancer Research (AACR)

Target Expression/Efficacy Relationship of XMT-1522, a HER2-targeting Antibody Drug Conjugate (ADC), in an Unselected Series of Non-small Cell Lung Cancer (NSCLC) Primary Human Carcinoma Xenografts.

AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Discovery of the novel, homogeneous payload platform Dolasynthen for Antibody-Drug Conjugates

AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Indole-Biaryl Pyrrolobenzodiazepines (I-BiPs): A Potent and Well-tolerated Class of DNA Mono-alkylating Payload for Antibody-Drug Conjugates (ADCs)

AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

MERS67 is a Novel anti-NaPi2b Antibody and Demonstrates Differential Expression Patterns in Lung Cancer Histologic Subtypes

International Association for the Study of Lung Cancer (IASLC)

Phase 1 dose escalation of XMT-1522, a novel HER2-targeting antibody-drug conjugate (ADC), in patients with HER2-expressing breast, lung and gastric cancer

American Society of Clinical Oncology (ASCO)

Unique Pharmacological Properties of Dolaflexin-Based ADCs – A Controlled Bystander Effect

American Association for Cancer Research (AACR)

Synergy of an anti-HER2 ADC TAK-522 (XMT-1522) in combination with anti-PD1 mAb in a syngeneic breast cancer model expressing human HER2

American Association for Cancer Research (AACR)

Relationship of NaPi2b expression and efficacy of XMT-1536, a NaPi2b targeting antibody drug conjugate (ADC), in an unselected panel of human primary ovarian mouse xenograft models

AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

A phase Ib, first-in-human, dose escalation and expansion study of XMT-1522, a novel antibody-drug conjugate (ADC) directed against HER2, in patients with advanced breast cancer and other advanced tumors expressing HER2

Non-clinical pharmacokinetics of XMT-1522, a HER2 targeting auristatin-based antibody drug conjugate

Combination of anti-HER2 ADC XMT-1522 and checkpoint inhibitor pembrolizumab for treatment of NSCLC in preclinical models​

A NaPi2b Antibody-Drug Conjugate Induces Durable Complete Tumor Regressions in Patient-Derived Xenograft Models of NSCLC

Discovery and preclinical development of a highly potent NaPi2b-targeted antibody-drug conjugate (ADC) with significant activity in patient-derived non-small cell lung cancer (NSCLC) xenograft models

Optimization of lead antibody selection for XMT-1522, a novel, highly potent HER2-targeted antibody-drug conjugate (ADC)

XMT-1522 induces tumor regressions in pre-clinical models representing HER2-positive and HER2 low-expressing breast cancer.

A Polymer-Based Antibody–Vinca Drug Conjugate Platform: Characterization and Preclinical Efficacy

A novel, highly potent HER2-targeted antibody-drug conjugate (ADC) for the treatment of low HER2-expressing tumors and combination with trastuzumab-based regimens in HER2-driven tumors

Trastuzumab-Dolaflexin, a Highly Potent Fleximer-Based Antibody-Drug Conjugate, Demonstrates a Favorable Therapeutic Index in Exploratory Toxicology Studies in Multiple Species

Poent Promise

Advantages of Polyacetal Polymer-based Antibody Drug Conjugates: Application to Low Expression Targets

Advantages of Polyacetal Polymer-Based Antibody Drug Conjugates Employing Cysteine Bioconjugation

Combination of anti-HER2 ADC XMT-1522 and checkpoint inhibitor pembrolizumab for treatment of NSCLC in preclinical models